The neurobiology of psychedelic drugs: implications for the treatment of mood disorders

By Franz X. Vollenweider, Michael Kometer. Nature Reviews Neuroscience, 2010

662 citations recorded by the source corpus.

Subfields: Biological Psychiatry, Cellular and Molecular Neuroscience, Clinical Psychology

View Paper: https://www.semanticscholar.org/paper/d95a57f4b1e3288f21a7dab08ebc2fd5ff10a762

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biological Psychiatry

In Cellular and Molecular Neuroscience

In Clinical Psychology

Citations in the corpus

Psychedelics Promote Structural and Functional Neural Plasticity (2018, background): “This indirect evidence has led to the reasonable hypothesis that psychedelics promote structural and functional neural plasticity, although this assumption had never been rigorously tested (Bogenschutz and Pommy, 2012; Vollenweider and Kometer, 2010).”
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial (2016, background): “Together, these data suggest that 5HT2A downregulation may explain some of the rapid and sustained anxiolytic effects of psilocybin (Vollenweider and Kometer, 2010).”
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study (2015, positive): “Although classic hallucinogens bind to many serotonin receptor subtypes and other receptors (Ray, 2010), the psychoactive effects of all classic hallucinogens appear to depend primarily on their actions at 5HT2A receptors (Nichols, 2004; Vollenweider and Kometer 2010; Vollenweider et al., 1998).”
Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial (2018, background): “Additionally, research with serotonergic psychedelics has gained momentum (Vollenweider and Kometer, 2010).”
Psychedelics (2016, background): “Vollenweider and Kometer (2010) suggested that indirect activation of glutamate networks by classic psychedelics may enhance neuroplasticity through stimulation of a-amino-3-hydroxy-5-methyl-4isoxazolepropionic acid–type glutamate receptors and subsequent increase in the level of BDNF. SerumBDNF…”
Of Roots and Fruits: A Comparison of Psychedelic and Nonpsychedelic Mystical Experiences (2017, background): “Perhaps due to activity in the serotonergic system, psychedelics may also have antidepressant effects (Vollenweider & Kometer, 2010) and may be useful in the treatment of clinical depression (Anderson, 2012).”
Pilot Study of the 5-HT2AR Agonist Psilocybin in the Treatment of Tobacco Addiction (2014, background): “Several plausible mechanisms of hallucinogen-facilitated treatments have been proposed (Bogenschutz and Pommy, 2012; Carhart-Harris et al., 2012, 2014; Ross, 2012; Vollenweider and Kometer, 2010).”
Mystical Experiences Occasioned by the Hallucinogen Psilocybin Lead to Increases in the Personality Domain of Openness (2011, background): “Recent reviews have suggested that hallucinogens could have positive effects on the outcomes of clinical disorders, particularly anxiety and mood disorders (Griffiths and Grob, 2010; Vollenweider and Kometer, 2010).”
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial (2016, background): “As a 5-HT2A agonist, the psilocybin metabolite psilocin directly and indirectly affects various brain cortical and subcortical areas and alters brain network dynamics (Carhart-Harris et al., 2012, 2014; Vollenweider and Kometer, 2010).”